Home › Products › Ophthalmology › Accentrix 2.3mg Injection

Accentrix 2.3mg Injection

Salt Composition: RANIBIZUMAB

₹17970.00₹22462.50

Inclusive of all taxes

Categories: Ophthalmology

Conditions: Diabetes Mellitus

Product Introduction

Accentrix 2.3mg injection contains the active ingredient Ranibizumab. It is an anti-neovascularisation agent in the class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It is used in adults to treat several eye diseases causing vision impairment. It is used to treat wet age-related macular degeneration (AMD, a persistent eye disease that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Accentrix is also used to treat myopic choroidal neovascularization (mCNV; a complication in near-sighted people where new blood vessels can grow in the back of the eye), and to treat macular oedema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss). It is also used to treat diabetic macular oedema (an eye disease caused by diabetes that can lead to vision loss) and diabetic retinopathy (damage to the eyes caused by diabetes).

Do not use Accentrix 2.3mg injection if you are allergic to Ranibizumab or other ingredients of this medicine. Do not take this medicine if you have an infection in or around your eye and if you have pain or redness in your eye.

Inform your doctor immediately if you develop symptoms such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision, or increased sensitivity to light. Inform your doctor if you have a prior history of eye conditions or eye treatments or had a stroke before initiating the treatment.

Uses

Accentrix 2.3mg injection is used to treat several eye diseases causing vision impairment, including, Age-related macular degeneration Macular edema Diabetic macular edema and retinopathy Myopic choroidal neovascularization Retinal vein occlusion

How it works

Accentrix 2.3mg injection specifically recognizes and binds to a protein called human vascular endothelial growth factor A (VEGF-A) present in the eye. In excess, VEGF-A causes abnormal blood vessel growth and swelling in the eye, leading to impairment of vision in certain eye diseases. This medicine can block its actions and prevent this abnormal growth and swelling. This injection can help to stabilize and improve your vision.

How to Use

Accentrix 2.3mg injection is administered as an injection into your eye by an eye doctor under a local anesthetic. Your doctor will decide the dose and frequency of the injection based on your disease condition. Do not self-administer the medicine.

Side Effects

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Pain and swelling in the eye Bleeding in the eye Blurred vision Urinary tract infection Skin rashes Discharge from the eye Serious Tear of the layer in the back of the eye Flashes of light in the eye Temporary loss of sight Clouding of lens Infection of the eyeball

Expert Tips

The use of Accentrix 2.3mg injection in children and adolescents has not been established and is therefore not recommended. This medicine can be used for people of 65 years of age and over with dose adjustments. If the eye becomes red, sensitive to light, painful, or develops a change in vision, seek immediate care from an ophthalmologist. Your doctor will monitor the condition of your eye and, depending on how you respond to the treatment, will decide if and when you need to receive further treatment.

References

  1. Lucentis 10 mg/ml solution for injection - Patient Information Leaflet (PIL) - (emc). www.medicines.org.uk. [Revised Nov 2022] [cited 2023 Jun 9]. Available from: https://www.medicines.org.uk/emc/product/307/pil
  2. Genentech, Inc, Lucentis [ranibizumab injection]. Access.fda.gov. [revised October 2014] [cited 2023 Jun 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf
  3. James E Frampton; Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration; Drugs & Aging; Published on May 2013; Accessed on June 09 2023; https://pubmed.ncbi.nlm.nih.gov/23539234/

Safety Advice

Pregnancy: unsafe Accentrix 2.3mg injection should not be used during pregnancy because it may cause risk to the unborn child. Inform your physician if you are pregnant, suspecting pregnancy, or planning to get pregnant during the treatment. Use effective contraception during treatment and at least three months after the last dose.

Lungs: Consult your doctor It is unknown whether Accentrix 2.3mg injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.

Breastfeeding: unsafe Accentrix 2.3mg injection should not be used in breastfeeding women because the medicine passes into the breast milk in small amounts and may harm your baby. Inform your physician if you are breastfeeding

Disclaimer

The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.

Written By: Muskan Patel, M.Pharm

Reviewed By: Dr. Vishwa Patel, MBBS